N-Terminal Pro-B-Type Natriuretic Peptide and Troponin Levels as Markers of Hemodynamic Stability in Very Low Birth Weight Infants During the First Days of Life

NCT ID: NCT00425581

Last Updated: 2008-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to test the hypothesis that there is an association between the hemodynamic status and the serum levels of NT-proBNP and cTnT in prematurely born infants. We would also evaluate the hypothesis that there is an association between the level of these proteins in the serum and the short and long term morbidity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NT-proBNP is a member of the natriuretic hormone family which plays an important role in regulation of extracellular fluid volume and blood pressure.It is secreted from the cardiac ventricle myocytes in response to myocardial stress. This hormone serves as a marker of ventricular dysfunction in adults but its role in newborns and especially preterm infants has not been well studied yet. Following birth of a healthy infant there is a surge in NT-proBNP levels which is then followed by a rapid decrease. One explanation for this surge is the transition in hemodynamics from fetal circulation into postnatal one. Few studies conducted in this area have shown association between NT-proBNP level and patency of ductus arteriosus and with respiratory distress syndrome of the newborn. Cardiac troponin T (cTnT)is a specific cardiac protein which serves as a specific indicator of cardiac damage in adults, it is usually not detected at birth but following myocardial injury its serum levels will slowly rise and generally will not be detectable until at least 4 hours after onset of injury. There is no "gold standard" test for diagnosis of hemodynamic instability in very low birth weight infants. Myocardial dysfunction is thought to be the major cause for this condition in VLBW population. Since this condition is associated with severe short and long term morbidity early recognition and specific treatment may be detrimental. We hypothesized that NT-proBNP and cTnT levels may serve as a more accurate markers for diagnosis, monitoring, and outcome prediction in VLBW infants during the first days of life, than the methods we currently use (blood pressure, urine output etc.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypotension Very Low Birth Weight Infants Ventricular Dysfunction Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* VLBW infants born at Sheba medical Center

Exclusion Criteria

* known cardiac or chromosomal anomaly
Minimum Eligible Age

1 Minute

Maximum Eligible Age

3 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheba Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sheba Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Iris Morag, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

References

Explore related publications, articles, or registry entries linked to this study.

Bar-Oz B, Lev-Sagie A, Arad I, Salpeter L, Nir A. N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem. 2005 May;51(5):926-7. doi: 10.1373/clinchem.2005.048892. No abstract available.

Reference Type BACKGROUND
PMID: 15855678 (View on PubMed)

Nasser N, Bar-Oz B, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr. 2005 Aug;147(2):248-53. doi: 10.1016/j.jpeds.2005.03.051. No abstract available.

Reference Type BACKGROUND
PMID: 16126059 (View on PubMed)

Makikallio K, Vuolteenaho O, Jouppila P, Rasanen J. Ultrasonographic and biochemical markers of human fetal cardiac dysfunction in placental insufficiency. Circulation. 2002 Apr 30;105(17):2058-63. doi: 10.1161/01.cir.0000015505.24187.fa.

Reference Type BACKGROUND
PMID: 11980685 (View on PubMed)

Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):293-321. doi: 10.1053/pcad.2002.24599.

Reference Type BACKGROUND
PMID: 12007084 (View on PubMed)

Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002 Jul;103(1):75-7. doi: 10.1042/cs1030075.

Reference Type BACKGROUND
PMID: 12095406 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SHEBA-06-4255-IM-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.